year 16, Issue 5 (September - October 2022)
Iran J Med Microbiol 2022, 16(5): 376-382 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Saedi E, Derakhshan M, Shamsian A A, Tahaghoghi Hajghorbani S, Movaqar A, Youssefi M. A Lamivudine/ Entacavir Resistance Mutations Among Treatment Naïve Chronic HBV Infected Patients Mashhad, Iran. Iran J Med Microbiol 2022; 16 (5) :376-382
URL: http://ijmm.ir/article-1-1476-en.html
URL: http://ijmm.ir/article-1-1476-en.html
Elaheh Saedi1 
, Mohammad Derakhshan1 
, Ali Akbar Shamsian2 , Sahar Tahaghoghi Hajghorbani2 , Aref Movaqar3 , Masoud Youssefi 4
, Mohammad Derakhshan1 , Ali Akbar Shamsian2 , Sahar Tahaghoghi Hajghorbani2 , Aref Movaqar3 , Masoud Youssefi 4
1- Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2- Department of Parasitology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3- Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
4- Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran , youssefim@mums.ac.ir
2- Department of Parasitology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3- Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
4- Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran , youssefim@mums.ac.ir
Abstract: (1638 Views)
Background and Aim: Despite significant progress in Hepatitis B Virus (HBV) treatment, the emergence of drug resistance mutations is a main challenging health threat. The data is lacking regarding circulation mutant strains in northeastern Iran; therefore, the present study was conducted to investigate HBV reverse transcriptase (RT) inhibitors drug resistance mutations in a group of treatment naïve patients in Mashhad, Iran.
Materials and Methods: In this study, 25 patients were included. The genomic DNA was extracted from serum samples, and the RT gene of HBV was amplified using specific primers. The PCR products were then subjected to gel electrophoresis and were next sent for sequencing. Finally, the sequences were analyzed using the HBVseq database, mutation list analysis software supported by Stanford University (https://hivdb.stanford.edu).
Results: The mean age of the patients was 42.7±16.5. Among the patients, 56% were men. Among 23 cases (92%), no resistance mutation was observed, while 2 cases showed mutations outside the YMDD motif of viral reverse transcriptase causing Lamivudine or Entecavir resistance. The detected mutations included: rt T184A, S202I, S202H, V180I, I169L, and V173L. All sequenced samples were identified as genotype D.
Conclusion: Lamivudine/Entecavir resistant variants are circulating in a minority of treatment naïve patients, which may indicate transmission of mutated stains to these patients or may be due to prolonged replication of the virus. This finding might be considered an alarm for increasing circulating mutant variants.
Type of Study: Original Research Article |
Subject:
Medical Virology
Received: 2021/09/8 | Accepted: 2022/04/19 | ePublished: 2022/08/8
Received: 2021/09/8 | Accepted: 2022/04/19 | ePublished: 2022/08/8
References
1. Organization WHO. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: accountability for the global health sector strategies 2016-2021: actions for impact: web annex 2: data methods. 2021.
2. Chang M-H. Natural history and clinical management of chronic hepatitis B virus infection in children. Hepatol Int. 2008;2(1):28-36. [DOI:10.1007/s12072-008-9050-9] [PMID] [PMCID]
3. Bagheri Amiri F, Mostafavi E, Mirzazadeh A. HIV, HBV and HCV coinfection prevalence in Iran-a systematic review and meta-analysis. PLoS One. 2016;11(3):e0151946. [DOI:10.1371/journal.pone.0151946] [PMID] [PMCID]
4. Nassal M. Hepatitis B viruses: reverse transcription a different way. Virus Res. 2008;134(1-2):235-49. [DOI:10.1016/j.virusres.2007.12.024] [PMID]
5. Newbold JE, Xin H, Tencza M, Sherman G, Dean J, Bowden S, et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virology. 1995;69(6):3350-7. [DOI:10.1128/jvi.69.6.3350-3357.1995] [PMID] [PMCID]
6. Köck J, Rösler C, Zhang J-J, Blum HE, Nassal M, Thoma C. Generation of covalently closed circular DNA of hepatitis B viruses via intracellular recycling is regulated in a virus specific manner. PLoS Pathog. 2010;6(9):e1001082. [DOI:10.1371/journal.ppat.1001082] [PMID] [PMCID]
7. Yeh C-T, Liang K-H, Chang M-L, Hsu C-W, Chen Y-C, Lin C-L, et al. Phenotypic and Genotypic Shifts in Hepatitis B Virus in Treatment-Naive Patients, Taiwan, 2008-2012. Emerg Infect Dis. 2017;23(5):820.
https://doi.org/10.3201/eid2305.161894 [DOI:10.3201/10.3201/eid2305.161894] [PMID] [PMCID]
8. Wu YF, Liao X, Liu JP. Sophorus species for chronic hepatitis B virus infection. Cochrane Database Syst Rev. 2018;2018(8). [DOI:10.1002/14651858.CD008957.pub2]
9. Tong S, Revill P. Overview of hepatitis B viral replication and genetic variability. J Hepatol. 2016;64(1):S4-S16. [DOI:10.1016/j.jhep.2016.01.027] [PMID] [PMCID]
10. Xu J, Wu B, Wang J-H, Huang L, Wang D-y, Zhao L, et al. Pre-existing mutations in reverse transcriptase of hepatitis B virus in treatment-naive Chinese patients with chronic hepatitis B. PLoS One. 2015;10(3):e0117429. [DOI:10.1371/journal.pone.0117429] [PMID] [PMCID]
11. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Investig. 2001;107(4):449-55. [DOI:10.1172/JCI11100] [PMID] [PMCID]
12. Lee HJ, Kim SJ, Kweon YO, Park SY, Heo J, Woo HY, et al. Evaluating the efficacy of switching from Lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients. PLoS One. 2018;13(1):e0190581. [DOI:10.1371/journal.pone.0190581] [PMID] [PMCID]
13. Rahimyan K, Vaezjalali M, Rostami M, Shokatpour N, Ahmadpour P. Prevalence of YMDD mutations in patients with chronic hepatitis B and renal transplant recipient patients after prolonged using of Lamivudine. Iran J Med Microbiol. 2016;9(4):73-8.
14. Almasi-Hashiani A, Ayubi E, Mansori K, Salehi-Vaziri M, Moradi Y, Gholamaliei B, et al. prevalence of hepatitis B virus infection among Iranian high risk groups: a systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench. 2018;11(2):91.
15. Ott J, Stevens G, Groeger J, Wiersma S. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212-9. [DOI:10.1016/j.vaccine.2011.12.116] [PMID]
16. Qian F, Qin J, Li D, Ma Z, Zhang H, Jin F, et al. Monitoring of genotypic resistance profile in chronic hepatitis B patients receiving nucleos (t) ide analogues in Huzhou, China. J Infect Dev Ctries. 2016;10(09):996-1002. [DOI:10.3855/jidc.8020] [PMID]
17. Zhang Q, Liao Y, Cai B, Li Y, Li L, Zhang J, et al. Incidence of natural resistance mutations in naïve chronic hepatitis B patients: A systematic review and meta‐analysis. J Gastroenterol Hepatol. 2015;30(2):252-61. [DOI:10.1111/jgh.12831] [PMID]
18. Gomes-Gouvêa MS, Ferreira AC, Teixeira R, Andrade JR, Ferreira A, Barros L, et al. HBV carrying drug-resistance mutations in chronically infected treatment-naive patients. Antivir Ther. 2015;20(4):387-95. [DOI:10.3851/IMP2938] [PMID]
19. Zhao Y, Wu J, Sun L, Liu G, Li B, Zheng Y, et al. prevalence of mutations in HBV DNA polymerase gene associated with nucleos (t) ide resistance in treatment-naive patients with Chronic Hepatitis B in Central China. Braz J Infect Dis. 2016;20 (2):173-8. [DOI:10.1016/j.bjid.2015.12.006] [PMID] [PMCID]
20. Günther S, Fischer L, Pult I, Sterneck M, Will H. Naturally occurring variants of hepatitis B virus. Advances in virus research. 52: Elsevier; 1999. p.25-137. [DOI:10.1016/S0065-3527(08)60298-5]
21. Locarnini S, Zoulim F. Molecular genetics of HBV infection. Antivir Ther. 2010;15(Suppl 3):3-14. [DOI:10.3851/IMP1619] [PMID]
22. Zhang X, Liu C, Gong Q, Zhang S, Zhang D, Lu Z, et al. Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy. J Gastroenterol Hepatol. 2003;18(12):1353-7. [DOI:10.1046/j.1440-1746.2003.03176.x] [PMID]
23. Paik YH, Chung HY, Ryu WS, Lee KS, Lee JS, Kim JH, et al. Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea. J Hepatol. 2001;35(1): 92-8. [DOI:10.1016/S0168-8278(01)00065-4]
24. Tan Y, Ding K, Su J, Trinh X, Peng Z, Gong Y, et al. The naturally occurring YMDD mutation among patients chronically infected HBV and untreated with Lamivudine: a systematic review and meta-analysis. PLoS One. 2012;7(3):e32789. [DOI:10.1371/journal.pone.0032789] [PMID] [PMCID]
25. Ziaee M, Javanmard D, Sharifzadeh G, Namaei MH, Azarkar G. Genotyping and mutation pattern in the overlapping MHR region of HBV isolates in Southern Khorasan, Eastern Iran. Hepat Mon. 2016;16(10). [DOI:10.5812/hepatmon.37806]
26. Zhao Y, Wu J, Sun L, Liu G, Li B, Zheng Y, et al. prevalence of mutations in HBV DNA polymerase gene associated with nucleos (t) ide resistance in treatment-naive patients with Chronic Hepatitis B in Central China. Brazilian Journal of Infectious Diseases. 2016;20(2):173-8. [DOI:10.1016/j.bjid.2015.12.006] [PMID] [PMCID]
27. Yuen LK, Locarnini SA. Genetic variability of hepatitis B virus and response to antiviral treatments: searching for a bigger picture. J Hepatol. 2009;50(3):445-8. [DOI:10.1016/j.jhep.2008.12.005] [PMID]
28. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos (t) ide analogues. Gastroenterology. 2009;137(5):1593-608. e2. [DOI:10.1053/j.gastro.2009.08.063] [PMID]
29. Hamidi-Fard M, Makvandi M, Samarbaf-Zadeh A, Hajiani E, Shayesteh A, Masjedizadeh A. Mutation analysis of hepatitis B virus reverse transcriptase region among untreated chronically infected patients in Ahvaz city (South-West of Iran). Indian J Med Microbiol. 2013;31(4):360. [DOI:10.4103/0255-0857.118882] [PMID]
30. Afshar RM, Mollaie HR. Use of ALLGIO probe assays for detection of HBV resistance to adefovir in patients with chronic hepatitis B, Kerman, Iran. Asian Pac J Cancer Prev. 2012;13(11):5463-7. [DOI:10.7314/APJCP.2012.13.11.5463] [PMID]
31. Khadem Ansari M, Rasmi Y, Abbasi L. Hepatitis B virus Genotypes in West Azarbayjan Province, Northwest Iran. Open Access Maced J Med Sci. 2017;5(7):875-879. [DOI:10.3889/oamjms.2017.206] [PMID] [PMCID]
32. Alavian S-M, Keyvani H, Rezaei M, Ashayeri N, Sadeghi HM. Preliminary report of hepatitis B virus genotype prevalence in Iran. World J Gastroenterol. 2006;12(32):5211.
33. Mojiri A, Behzad-Behbahani A, Saberifirozi M, Ardabili M, Beheshti M, Rahsaz M, et al. Hepatitis B virus genotypes in southwest Iran: molecular, serological and clinical outcomes. World J Gastroenterol. 2008;14(10):1510. [DOI:10.3748/wjg.14.1510] [PMID] [PMCID]
34. Haghshenas MR, Arabi M, Mousavi T. Hepatitis B genotypes in iran. Mater Socio Med. 2014;26 (2):129. [DOI:10.5455/msm.2014.26.129-133] [PMID] [PMCID]
35. Croagh CM, Desmond PV, Bell SJ. Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance. World J Hepatol. 2015;7(3):289. [DOI:10.4254/wjh.v7.i3.289] [PMID] [PMCID]
36. Clarke B, Bloor S. Molecular genotyping of hepatitis B virus. J Clin Virol. 2002;25:41-5. [DOI:10.1016/S1386-6532(02)00193-2]
37. Dokanehiifard S, Bidmeshkipour A. Study of hepatitis b virus (hbv) genotypes in kermanshah province, west of Iran. J Biol Sci. 2009;1(1):113-20.
38. Neisi N, Makvandi M, Samarbaf Zadeh AR. A study on genotypes of hepatitis B virus among hemodialysis patients in Khuzestan province. Jundishapur J Microbiol. 2011;4(2):65-70.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright Policy
Iranian Journal of Medical Microbiology by Farname is licensed under CC BY-NC 4.0
